Therapeutics Targeting the Gut Microbiome: Rigorous Pipelines for Drug Development

Kate A Markey; Marcel R M van den Brink; Jonathan U Peled

doi:10.1016/j.chom.2020.01.022

Therapeutics Targeting the Gut Microbiome: Rigorous Pipelines for Drug Development

Cell Host Microbe. 2020 Feb 12;27(2):169-172. doi: 10.1016/j.chom.2020.01.022.

Authors

Kate A Markey¹, Marcel R M van den Brink², Jonathan U Peled³

Affiliations

¹ Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: markeyk@mskcc.org.
² Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.

PMID: 32053786
DOI: 10.1016/j.chom.2020.01.022

Abstract

Restoration of the gut microbiome is a promising preventive and therapeutic strategy in a number of clinical scenarios. We discuss here the scientific and clinical challenges of engineering and implementing these strategies.

Therapeutics Targeting the Gut Microbiome: Rigorous Pipelines for Drug Development

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding